|Bid||19.85 x 3000|
|Ask||24.89 x 2900|
|Day's Range||18.89 - 20.50|
|52 Week Range||7.80 - 43.00|
|Beta (5Y Monthly)||1.26|
|PE Ratio (TTM)||25.75|
|Earnings Date||Feb 08, 2022 - Feb 14, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
MIDLAND, TX, June 27, 2022 (GLOBE NEWSWIRE) -- Mexco Energy Corporation (NYSE American: MXC) reported results on its Annual Report, Form 10-K to the Securities and Exchange Commission for the fiscal year ended March 31, 2022. The Company reported net income of $2,855,066 or $1.36 per diluted share, for fiscal year 2022, compared to net income of $155,932, or $0.08 per diluted share, for fiscal 2021. Operating revenues in fiscal 2022 were $6,587,780, an increase of 135% when compared to fiscal 20
MGC Pharmaceuticals Ltd. (LSE: MXC, ASX: MXC, OTC:MGCLF), a European based bio-pharma company specializing in the production and development of phytomedicines, has signed an exclusive distribution agreement with Sciensus Rare, a part of UK health care group, Sciensus, for the distribution of CannEpil® and CogniCann® in key European territories and the UK.
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...